VuMedi is a video-sharing website for surgeons in the orthopedic, cardiovascular, neurosurgery, and radiology sectors.
VuMedi is a video-sharing website for surgeons in the orthopedic, cardiovascular, neurosurgery, and radiology sectors.
Educational Software📍 Oakland, CAFounded 2008
Current Valuation
$535M
as of 2025-Q2
PRIVATE
QL Price
$259.64M
-51% vs last round
QuantLogix's current estimate for VuMedi, published 2026-09-27 — below the last disclosed round of $535M (2025-Q2).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$535M
2025-Q2
weight 0.42
Secondary market print
$57.78M
2026-06-27
weight 0.58
How this price has held up
No round has priced for VuMedi since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, VuMedi, 2026-09-27 (150ee495d5c2ff62).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is VuMedi going public?
No. VuMedi is private and has not filed to go public. There is no S-1 on file.
What is VuMedi's valuation in 2026?
VuMedi is valued at $535M as of 2025-Q2, set by its Series B ($79.98M, May 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has VuMedi filed an S-1?
No public S-1 is on file for VuMedi.
How much has VuMedi raised?
VuMedi has raised $82.08M in total, most recently a Series B of $79.98M in May 2025.
Is VuMedi publicly traded — can you buy VuMedi stock?
No. VuMedi is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for VuMedi on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2008
HQ
Oakland, CA
Employees
286
Total Raised
$82.08M
Last Round
Series B — $79.98M (May 2025)
IPO Status
private
Fundraising Status
Series B · $79.98M · 1y 4mo ago
privateTotal raised $82.08M
Secondary Market
Implied price / share
$2.28
Last round price / share
$21.13
vs last round
-89.2%
Open interest
1
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series B
$79.98M
May 2025
—
$535M
Talent Signal
Hiring trend
▼ Hiring downtrend
-45% vs 2026-08
Open roles
6
via greenhouse
Product-build share
50%
engineering, research, product, design
Trajectory
tightening
product-led hiring — 50% of open roles build product; the rest are go-to-market and G&A.
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Principal ML Engineer, Recommendation SystemsPrincipal Software EngineerSenior Software EngineerDirector of Pharmaceutical PartnershipsDirector of Product Marketing Vice President, Sales
Counted from VuMedi's live job board as of 2026-09-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
EdTechEducationHealth CareMedicalVideo
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q2. Refreshed quarterly.